Table 1 Demographics and treatment history of 236 chronic-phase CML patients who discontinued TKI treatment in DMR in Spain from April 2009 to February 2018

From: Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients

Age at diagnosis, yeara 50 (40–61)
Age at TKI discontinuation, yeara 61 (52–72)
Sex, females (%) 123 (52)
Sokal risk score, n (%)  
 Low 129 (60)
 Intermediate 69 (32)
 High 17 (8)
 Unknown 21
Time from diagnosis to TKI discontinuation, monthsa 130 (96–162)
Prior interferon treatment, n (%) 55 (23)
TKI lines before TKI discontinuation, n (%)  
 One 184 (78)
 Two 32 (14)
 Three 20 (8)
TKI at the time of treatment cessation, n (%)  
 Imatinib 175 (74)
 Nilotinib 41 (17.5)
 Dasatinib 17 (7)
 Bosutinib 1 (0.5)
 Ponatinib 2 (1)
History of resistance to any TKI, n (%) 17 (7)
Duration of TKI treatment, monthsa 123.5 (93–150)
Time in MR4.5 before TKI discontinuation, monthsa 68 (40–100)
  1. DMR deep molecular response, TKI tyrosine kinase inhibitor
  2. aMedian (interquartile range)